Drug Discovery Technologies

We invest in Machine learning-enabled, fit-for-purpose chemical and biologics design companies that are supplanting inefficient, time-consuming and expensive library screening methods for biopharma drugs. We believe ML models will integrate large data sets to gain a deeper understanding of disease mechanisms to uncover new molecular targets.

We are interested in companies incorporating advanced microscopy and imaging technologies in hopes of better visualizing disease processes in real time and incorporating these findings into their models. Also, we are interested in start-ups investigating the function of the dark, or noncoding, genome in disease pathology.